|
74 Companies |
|
57 Products |
|
57 Products |
|
42 Mechanisms of Action |
|
2 Trials |
|
680 News |
|
| «12...234567891011121314» |
- | New P4 trial: The Flocked Swab and the Traditional Fiber Swab for the Diagnosis of the Herpes Simplex Epithelial Keratitis (clinicaltrials.gov) - Jan 22, 2014
P4, N=250, Recruiting, Sponsor: Centre Hospitalier Universitaire de Québec, CHU de Québec
- Kepivance (palifermin) / SOBI, Amgen
New P1/2 trial: Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis (clinicaltrials.gov) - Jan 12, 2014
P1/2, N=5, Recruiting, Sponsor: Brett King
- Kepivance (palifermin) / SOBI, Amgen
Enrollment open: Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis (clinicaltrials.gov) - Jan 12, 2014
P1/2, N=5, Recruiting, Sponsor: Brett King
Not yet recruiting --> Recruiting
- | flucloxacillin sodium / Generic mfg.
New P4 trial: DANCE: Duration of ANtibiotic Therapy for CEllulitis (clinicaltrials.gov) - Jan 8, 2014
P4, N=396, Not yet recruiting, Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- ||| Altabax (retapamulin) / GSK, Almirall
Enrollment open: ALTARGOPMS: ALTARGO(Retapamulin) PMS(Post-marketing Surveillance) (clinicaltrials.gov) - Jan 8, 2014
P=N/A, N=3000, Recruiting, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- ||||| VCL-HB01 / Brickell
New P1/2 trial: Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in Adults (clinicaltrials.gov) - Jan 6, 2014
P1/2, N=156, Recruiting, Sponsor: Vical
- amphotericin b liposome / Generic mfg.
New P3 trial: Liposomal Amphotericin in Disseminated Leishmaniasis (clinicaltrials.gov) - Dec 30, 2013
P3, N=20, Completed, Sponsor: Hospital Universitário Professor Edgard Santos
- ||||| New P2 trial: A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of Molluscum Contagiosum (clinicaltrials.gov) - Dec 29, 2013
P2, N=200, Not yet recruiting, Sponsor: ViroXis Corporation
- amphotericin b liposome / Generic mfg.
Trial completion: Liposomal Amphotericin in Disseminated Leishmaniasis (clinicaltrials.gov) - Dec 29, 2013
P3, N=20, Completed, Sponsor: Hospital Universitário Professor Edgard Santos
Active, not recruiting --> Recruiting Not yet recruiting --> Completed
- ||||| New P2 trial: Efficacy and Safety Study of ME1111 in Patients With Onychomycosis (clinicaltrials.gov) - Dec 25, 2013
P2, N=300, Recruiting, Sponsor: Meiji Seika Pharma Co., Ltd.
- | pentoxifylline / Generic mfg.
Enrollment closed: Antimony Plus Pentoxifylline in Cutaneous Leishmaniasis (clinicaltrials.gov) - Dec 25, 2013
P2/3, N=164, Active, not recruiting, Sponsor: Paulo Roberto Lima Machado
Not yet recruiting --> Completed Recruiting --> Active, not recruiting
- ||||||| Trial completion: Evaluate the Clinical Equivalence of Two Naftifine HCl 1% Creams in Patients With Interdigital Tinea Pedis (clinicaltrials.gov) - Dec 18, 2013
P3, N=1053, Completed, Sponsor: Taro Pharmaceuticals USA
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| clotrimazole topical / Generic mfg.
Trial completion: Evaluate the Safety & Bioequivalence of a Generic Butenafine Cream & Lotrimin Ultra (clinicaltrials.gov) - Dec 18, 2013
P1, N=707, Completed, Sponsor: Taro Pharmaceuticals USA
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Trial completion: A Therapeutic Equivalence Study of Two Oxiconazole Nitrate Topical Cream Treatments for Patients With Tinea Pedis (clinicaltrials.gov) - Dec 18, 2013
P1, N=661, Completed, Sponsor: Taro Pharmaceuticals USA
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | New P2 trial: A Trial of the Efficacy and Safety of Topical Nitric Oxide in Patients With Anogenital Warts (clinicaltrials.gov) - Dec 17, 2013
P2, N=299, Completed, Sponsor: University of Aberdeen
- |||||| Sivextro (tedizolid) / Merck (MSD), Nabriva Therap
Enrollment open: Safety and Efficacy of BAY1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections (clinicaltrials.gov) - Dec 14, 2013
P3, N=150, Recruiting, Sponsor: Bayer
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Trial completion: Pharmacokinetics and Safety Study of ME1111 in Moderate to Severe Onychomycosis Patients (clinicaltrials.gov) - Dec 14, 2013
P1, N=24, Completed, Sponsor: Meiji Seika Pharma Co., Ltd.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- || amphotericin b liposome / Generic mfg.
New P3 trial, Combination therapy, Monotherapy: Efficacy Trial of Ambisome Given Alone and Ambisome Given in Combination With Miltefosine for the Treatment of VL HIV Positive Ethiopian Patients. (clinicaltrials.gov) - Dec 12, 2013
P3, N=132, Not yet recruiting, Sponsor: Drugs for Neglected Diseases
- Enrollment change: Topical 3% Amphotericin B Cream for the Treatment of Cutaneous Leishmaniasis in Colombia (clinicaltrials.gov) - Dec 12, 2013
P1/2, N=80, Recruiting, Sponsor: Drugs for Neglected Diseases
Active, not recruiting --> Completed N=202 --> 80
- Trial completion: A Trial of the Efficacy and Safety of Topical Nitric Oxide in Patients With Anogenital Warts (clinicaltrials.gov) - Dec 11, 2013
P2, N=299, Completed, Sponsor: University of Aberdeen
N=202 --> 80 Not yet recruiting --> Completed
- Enrollment closed: LEISH-F3 + GLA-SE and the LEISH-F3 + MPL-SE Vaccine (clinicaltrials.gov) - Dec 11, 2013
P1, N=48, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Completed Recruiting --> Active, not recruiting
- drospirenone/ethinyl estradiol / Generic mfg.
Enrollment change: A Study to Examine the Safety and Efficacy of Drospirenone and Ethinyl Estradiol (YAZ) Versus Placebo In HS (clinicaltrials.gov) - Dec 1, 2013
P2, N=4, Terminated, Sponsor: Massachusetts General Hospital
Recruiting --> Active, not recruiting N=40 --> 4
- | Cubicin (daptomycin) / Merck (MSD)
Trial suspension, Gram positive: Safety and Efficacy Study of Daptomycin in Pediatric Participants (1 to 17 Years-old) With Skin and Skin Structure Infections (clinicaltrials.gov) - Nov 26, 2013
P4, N=420, Suspended, Sponsor: Cubist Pharmaceuticals
N=40 --> 4 Recruiting --> Suspended
- | Enrollment change: Zinc for the Treatment of Herpes Simplex Labialis (HSL) (clinicaltrials.gov) - Nov 18, 2013
P3, N=157, Completed, Sponsor: Integrative Medicine Institute
Recruiting --> Suspended N=106 --> 157
- gentamicin sulfate / Generic mfg.
New P2 trial: PAGELEC: WR 279,396 for the Treatment of Cutaneous Leishmaniasis (clinicaltrials.gov) - Nov 18, 2013
P2, N=30, Recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
- | Trial completion: Zinc for the Treatment of Herpes Simplex Labialis (HSL) (clinicaltrials.gov) - Nov 18, 2013
P3, N=157, Completed, Sponsor: Integrative Medicine Institute
N=106 --> 157 Recruiting --> Completed
- acyclovir / Generic mfg.
Enrollment change: A Study to Describe the Pharmacokinetics of Acyclovir in Premature Infants (PTN_Acyclo) (clinicaltrials.gov) - Nov 18, 2013
P1, N=32, Completed, Sponsor: Phillip Brian Smith
Recruiting --> Completed N=20 --> 32
- |||||||||| Baxdela (delafloxacin) / Menarini, Melinta Therap
New P3 trial: Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections (clinicaltrials.gov) - Nov 13, 2013
P3, N=660, Not yet recruiting, Sponsor: Melinta Therapeutics, Inc.
- ||||| New P2 trial: Safety and Efficacy of Merlin (Ethanol and Glycolic Acid Mixture) for the Treatment of Cold Sores (clinicaltrials.gov) - Nov 13, 2013
P2, N=480, Active, not recruiting, Sponsor: Topical Remedy
- Trial completion: Oral Zinc Gluconate as Treatment for Recalcitrant Cutaneous Warts: A Randomized, Double-blind, Placebo-controlled Trial (clinicaltrials.gov) - Nov 12, 2013
P2/3, N=28, Completed, Sponsor: Philippine Dermatological Society
N=20 --> 32 Recruiting --> Completed
- Fexinidazole Winthrop (fexinidazole) / Sanofi
Enrollment open: Trial to Determine Efficacy of Fexinidazole in Visceral Leihmaniasis Patients in Sudan (clinicaltrials.gov) - Nov 11, 2013
P2, N=66, Recruiting, Sponsor: Drugs for Neglected Diseases
Recruiting --> Completed Not yet recruiting --> Recruiting
- | Fexinidazole Winthrop (fexinidazole) / Sanofi
New P2 trial: Trial to Determine Efficacy of Fexinidazole in Visceral Leihmaniasis Patients in Sudan (clinicaltrials.gov) - Nov 6, 2013
P2, N=66, Recruiting, Sponsor: Drugs for Neglected Diseases
- New P4 trial, IO biomarker: A Study to Explore Association of Treatment Regimens for Visceral Leishmaniasis, Host Immunological, Genetical and Nutrition Factors With Post-kala-azar Dermal Leishmaniasis (PKDL) (clinicaltrials.gov) - Oct 31, 2013
P4, N=36, Active, not recruiting, Sponsor: International Centre for Diarrhoeal Disease Research, Bangladesh
- Clinical: Predictors of Failure of Empiric Outpatient Antibiotic Therapy in Emergency Department Patients With Uncomplicated Cellulitis. (clinicaltrials.gov) - Oct 28, 2013
P=N/A, N=500, Completed, Sponsor: Lawson Health Research Institute
- Enrollment open: Resin vs. Amorolfine vs. Terbinafine Treatment in Onychomycosis (clinicaltrials.gov) - Oct 28, 2013
P=N/A, N=90, Enrolling by invitation, Sponsor: Helsinki University Central Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Enrolling by invitation
- Enrollment open: Squarex: Safety and Efficacy of Squaric Acid Dibutyl Ester for the Treatment of Herpes Labialis (clinicaltrials.gov) - Oct 28, 2013
P1, N=60, Recruiting, Sponsor: Massachusetts General Hospital
Not yet recruiting --> Enrolling by invitation Not yet recruiting --> Recruiting
- Trial completion: Extracorporeal Shock Wave Treatment for Cellulite (clinicaltrials.gov) - Oct 27, 2013
P=N/A, N=14, Completed, Sponsor: Concept-Clinic
Not yet recruiting --> Recruiting Not yet recruiting --> Completed
- New P1 trial: Squarex: Safety and Efficacy of Squaric Acid Dibutyl Ester for the Treatment of Herpes Labialis (clinicaltrials.gov) - Oct 27, 2013
P1, N=60, Recruiting, Sponsor: Massachusetts General Hospital
- | Enrollment closed: Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients With Pentamidine: a Cohort Study (clinicaltrials.gov) - Oct 27, 2013
P3, N=72, Active, not recruiting, Sponsor: Institute of Tropical Medicine, Belgium
Not yet recruiting --> Completed Recruiting --> Active, not recruiting
- |||||||||| Sivextro (tedizolid) / Merck (MSD), Nabriva Therap
New P3 trial: Safety and Efficacy of BAY1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections (clinicaltrials.gov) - Oct 20, 2013
P3, N=150, Recruiting, Sponsor: Bayer
- |||||||||| Amenalief (amenamevir) / Maruho
New P3 trial: Phase III Study of ASP2151 in Herpes Simplex Patients (clinicaltrials.gov) - Oct 8, 2013
P3, N=453, Enrolling by invitation, Sponsor: Maruho Co., Ltd.
- |||||| Amenalief (amenamevir) / Maruho
Enrollment open: Phase III Study of ASP2151 in Herpes Simplex Patients (clinicaltrials.gov) - Oct 7, 2013
P3, N=453, Enrolling by invitation, Sponsor: Maruho Co., Ltd.
Recruiting --> Active, not recruiting Not yet recruiting --> Enrolling by invitation
- || New P3 trial: High Dose Fluconazole in Cutaneous Leishmaniasis in Bahia and Manaus (clinicaltrials.gov) - Sep 29, 2013
P3, N=140, Not yet recruiting, Sponsor: Hospital Universitário Professor Edgard Santos
- | Trial completion: A Study of Caspofungin (MK-0991) in Japanese Children and Adolescents With Documented Candida or Aspergillus Infections (MK-0991-074) (clinicaltrials.gov) - Sep 24, 2013
P2, N=20, Completed, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Enrolling by invitation Active, not recruiting --> Completed
- | mupirocin / Generic mfg.
Trial completion: PRIMO: A Randomized Clinical Trial to Prevent Recurrent CA-MRSA Infection (clinicaltrials.gov) - Sep 24, 2013
P3, N=350, Completed, Sponsor: Los Angeles Biomedical Research Institute
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | acyclovir / Generic mfg.
Enrollment change: Acyclovir in Preventing Herpes Simplex Virus Infection in Patients With Neutropenia (clinicaltrials.gov) - Sep 23, 2013
P3, N=112, Active, not recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Active, not recruiting --> Completed N=200 --> 112
- | Enrollment change: Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous Leishmaniasis (clinicaltrials.gov) - Sep 17, 2013
P3, N=264, Recruiting, Sponsor: Oswaldo Cruz Foundation
N=200 --> 112 N=340 --> 264
- ||||| Cresemba (isavuconazonium sulfate) / Astellas, Basilea, Pfizer, Laboratoire Riva, Asahi Kasei
Enrollment closed: VITAL: Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi (clinicaltrials.gov) - Sep 12, 2013
P3, N=150, Active, not recruiting, Sponsor: Astellas Pharma Inc
N=340 --> 264 Recruiting --> Active, not recruiting
- |||| Naftin (naftifine hydrochloride) / Merz Pharma
Trial completion: Pharmacokinetic Study of Pediatric Subjects With Tinea Cruris and Tinea Pedis (clinicaltrials.gov) - Sep 12, 2013
P4, N=65, Completed, Sponsor: Merz Pharmaceuticals, LLC
Recruiting --> Active, not recruiting Recruiting --> Completed
- | OrienX010 / OrienGene
New P1 trial: A Phase I Study of Recombinant hGM-CSF Herpes Simplex Virus to Treat Cancer (clinicaltrials.gov) - Sep 3, 2013
P1, N=18, Recruiting, Sponsor: OrienGene Biotechnology Ltd.